Clinical trial
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced…
NCT00066443 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00066443 |
|---|---|
| Title | Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer |
| Official title | A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | pegfilgrastim, docetaxel, epirubicin hydrochloride |
| Enrollment | 93 |
| Start date | Nov 3, 2003 |
| Primary completion | Jan 6, 2010 |
| Completion | Jan 16, 2014 |
| First posted | Aug 7, 2003 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: